Form 4: Sana Biotechnology CEO Steve Harr Acquires Stock Options and Restricted Stock Units
SEC Form 4
Sana Biotechnology's CEO, Steve Harr, acquired 900,000 stock options and 200,000 restricted stock units on March 7, 2024, according to a Form 4 filing.
Summary
- On March 7, 2024, Steve Harr, the President and CEO of Sana Biotechnology, acquired 900,000 stock options and 200,000 restricted stock units (RSUs).
- The stock options have an exercise price of $9.58 and expire on March 6, 2034.
- The RSUs vest in four equal annual installments starting March 7, 2025, and the stock options vest as to 25% on March 7, 2025, and then in 36 equal monthly installments thereafter, contingent upon continued service to Sana.
- Following these transactions, Harr directly owns 900,000 stock options and 200,000 RSUs.
Sentiment
Score: 6
Explanation: The document is a standard regulatory filing detailing executive compensation. It's neutral in tone and doesn't contain any information that would significantly impact investor sentiment positively or negatively.
Positives
- The grant of stock options and RSUs to the CEO aligns his interests with those of the shareholders, incentivizing him to increase the company's value.
- The vesting schedules for both the options and RSUs encourage long-term commitment from the CEO.
Future Outlook
The vesting schedules of the RSUs and stock options suggest an expectation of continued service and leadership from the CEO over the next several years.
Industry Context
Stock option and RSU grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align management's interests with those of shareholders. The vesting schedules are typical for such grants.
Comparison to Industry Standards
- Executive compensation packages in the biotechnology industry often include a mix of salary, stock options, and restricted stock units.
- Vesting schedules for stock options and RSUs typically range from three to five years, aligning with industry norms.
- Companies like Amgen, Gilead Sciences, and Biogen also utilize similar compensation structures for their executives.
Stakeholder Impact
- Shareholders may view the grant of stock options and RSUs as a positive sign, aligning management's interests with their own.
- Employees may see this as a sign of confidence in the company's future.
Key Dates
| Date | Description |
|---|---|
| 03/07/2024 | Date of transaction: CEO acquired stock options and restricted stock units |
| 03/07/2025 | First vesting date for 25% of stock options and first vesting date for RSUs |
| 03/06/2034 | Expiration date of the stock options |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.